研究者詳細 - 今井　則博

論文 - 今井　則博

分割表示 112 件中 81 - 100 件目／全件表示 >>

Hepatology Highlights.

Shah PA, Lau DTY, Russo NW, Brown RS Jr, Maiers JL, Schwartz RE, Imai N, Krisko TI, Navarro-Corcuera A, Jalan-Sakrikar N, Pisa JF, Jesudian AB, Tafesh ZH, Fortune BE, Kostallari E

Hepatology (Baltimore, Md.) 71 巻 ( 1 ) 頁： 1 - 3 2020年1月

Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD

Imai Norihiro, Cohen David E.

HEPATOLOGY 68 巻 ( 6 ) 頁： 2062 - 2065 2018年12月

Hepatocyte-specific depletion of ubiquitin regulatory X domain containing protein 8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model

Imai Norihiro, Suzuki Michitaka, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Ishikawa Tetsuya, Goto Hidemi, Fujimoto Toyoshi

HISTOCHEMISTRY AND CELL BIOLOGY 148 巻 ( 3 ) 頁： 219 - 227 2017年9月

Hepatocyte-Specific Depletion of UBXD8 Induces Periportal Steatosis in Mice Fed a High-Fat Diet

Imai Norihiro, Suzuki Michitaka, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Abe Takaya, Shioi Go, Goto Hidemi, Fujimoto Toyoshi

PLOS ONE 10 巻 ( 5 ) 頁： e0127114 2015年5月

Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.

Imai N, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Hirooka Y, Goto H

World journal of hepatology 6 巻 ( 12 ) 頁： 844 - 50 2014年12月

当院におけるHBV感染と肝発癌の検討

荒川恭宏, 加藤幸一郎, 新家卓郎, 今井則博, 阿知波宏一, 山田恵一, 石津洋二, 葛谷貞二, 本多隆, 林和彦, 石上雅敏, 後藤秀実

肝臓 55 巻 ( Suppl.2 ) 頁： A599 - A599 2014年9月

The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma

Kuzuya T

Acta Hepatologica Japonica 54 巻 ( 7 ) 頁： 505 - 506 2013年5月

掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Hepatologica Japonica

We investigated the relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma (HCC). Subjects were 64 patients who began sorafenib therapy. Contrast enhanced CT images were taken at baseline and after 2 weeks of sorafenib treatment. In patients with fever, the ratio of patients demonstrating the disappearance or decrease of lesion contrast on contrast enhanced CT images was significantly higher than in those without fever (91.3% and 61.0%, respectively, p=0.010, Fisher's exact probability test). The results suggested the relationship between the fever and contrast change on contrast enhanced CT.

DOI： 10.2957/kanzo.54.505

Scopus

researchmap

Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.

Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Gut and liver 7 巻 ( 2 ) 頁： 246 - 51 2013年3月

Clinical trial of percutaneous radio frequency ablation therapy by two-step insertion method using VirtuTRAX™ instrument navigator

Kuzuya T

Acta Hepatologica Japonica 54 巻 ( 12 ) 頁： 850 - 853 2013年

掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Hepatologica Japonica

We performed percutaneous radio frequency ablation (RFA) therapy by two-step insertion method using VirtuTRAXTM (GE Healthcare, USA) instrument navigator. Subjects were 16 patients (23 nodules) with hepatocellular carcinoma. VirtuTRAXTM position sensor was attached to the hilt of 14-gauge outer needle. In all cases, we could perform 17- gauge Cool-tip RFA without the positional gap between the virtual tract and the actual needle which was caused by the deflection of the needle. The reasons without causing the positional gap were that the outer needle was more rigid than Cool-tip needle, and that it was inserted using initial insertion of a 21-gauge guided needle. RFA by two-step insertion method using VirtuTRAXTM is suggested to be more safe and effective than conventional RFA.

DOI： 10.2957/kanzo.54.850

Scopus

researchmap

An Increase in Lesion Density can Predict Lower Local Recurrence after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

Imai Norihiro, Katano Yoshiaki, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Itoh Akihiro, Hirooka Yoshiki, Goto Hidemi

HEPATO-GASTROENTEROLOGY 60 巻 ( 125 ) 頁： 965 - 970 2013年

Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load

ARASE Yasuji, SUZUKI Yoshiyuki, SUZUKI Fumitaka, AKUTA Norio, SEZAKI Hitomi, KAWAMURA Yusuke, KOBAYASHI Masahiro, IMAI Norihiro, SEKO Yuya, HOSAKA Tetsuya, MATSUMOTO Naoki, SAITO Satoshi, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

Hepatology research : the official journal of the Japan Society of Hepatology 42 巻 ( 8 ) 頁： 750 - 756 2012年8月

ミリプラチン動注化学療法を併用したラジオ波凝固療法

今井則博, 池田健次, 瀬古裕也, 原祐, 大野敦司, 松本直樹, 川村祐介, 保坂哲也, 小林正宏, 斎藤聡, 瀬崎ひとみ, 芥田憲夫, 鈴木文孝, 鈴木義之, 荒瀬康司, 熊田博光

肝臓 53 巻 ( 6 ) 頁： 351-354 - 354 2012年6月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：一般社団法人　日本肝臓学会

Miriplatin is a platinum complex developed to treat hepatocellular carcinoma (HCC) via administration into the hepatic artery as a sustained-release suspension in iodized oil. We retrospectively evaluated the efficacy of combination therapy with transcatheter arterial infusion chemotherapy using miriplatin and percutaneous radiofrequency ablation for HCC in 11 patients. Immediately after transcatheter arterial infusion chemotherapy using miriplatin, we performed radiofrequency ablation. The greatest long-axis and short-axis dimensions of the area coagulated after combination therapy were 42 mm (35-80 mm) and 34 mm (32-60 mm), respectively. During follow-up (median 12 months), there was no recurrence from the same subsegment. No serious adverse events were observed. These results suggested that using the combination therapy, it is possible to finish one treatment session for patient with HCC.

DOI： 10.2957/kanzo.53.351

researchmap

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL

Matsumoto, N; Arase, Y; Seko, Y; Imai, N; Kawamura, Y; Sezaki, H; Hosaka, T; Akuta, N; Kobayashi, M; Kobayashi, M; Suzuki, Y; Saito, S; Suzuki, F; Ikeda, K; Kumada, H; Aida, K; Kobayashi, T

HEPATOLOGY RESEARCH 42 巻 ( 6 ) 頁： 558 - 563 2012年6月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Hepatology Research

Aim: The aim of this study was to evaluate the prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhotic patients with fasting plasma glucose (FPG) level of <126mg/dL. Methods: A total of 263 patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) positive liver cirrhosis, FPG level of <126mg/dL, and had diabetes status evaluated by the use of 75-g oral glucose tolerance test (OGTT), were enrolled in this study. Plasma glucose and insulin levels were analyzed periodically for 3h after oral glucose loading. Diabetes was defined as a 2-h post-load glucose on the OGTT of ≥200mg/dL. The prevalence of diabetes by use of OGTT and predictive factors for diabetes were evaluated by the use of the Mann-Whitney U-test, Fisher's exact probability test or multivariate analysis by logistic regression. Hypoalbuminemia was defined as serum albumin level of <3.9g/dL. Elevated indocyanine green retention rate at 15min (ICG R15) was regarded as ≥ 25%. Results: Out of 263 patients, 44 (16.7%) were diagnosed as having diabetes. Multivariate analysis showed that diabetes occurred when patients had hypoalbuminemia of <3.9g/dL (odds ratio [OR] 2.33; 95% confidential interval [CI]=1.04-5.24; P=0.040) and ICG R15 of <25% (OR 2.36; 95%CI=1.01-5.58). Conclusions: Hypoalbuminemia and elevated ICG R15 in hepatitis virus related cirrhotic patients with FPG level of <126mg/day enhance diabetes pattern after OGTT with significant difference. © 2012 The Japan Society of Hepatology.

DOI： 10.1111/j.1872-034X.2011.00957.x

Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderlv patients

ARASE Yasuji, KOBAYASHI Mariko, SUZUKI Fumitaka, SUZUKI Yoshiyuki, KAWAMURA Yusuke, AKUTA Norio, IMAI Norihiro, KOBAYASHI Masahiro, SEZAKI Hitomi, MATSUMOTO Naoki, SAITO Satoshi, HOSAKA Tetsuya, IKEDA Kenji, KUMADA Hiromitsu, OHMOTO Yuki, AMAKAWA Kazuhisa, HSIEH Shiun Dong, OGAWA Kyoko, TANABE Maho, TSUJI Hiroshi, KOBAYASHI Tetsuro

Hepatology research : the official journal of the Japan Society of Hepatology 42 巻 ( 3 ) 頁： 264 - 272 2012年3月

Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Japanese journal of clinical oncology 42 巻 ( 3 ) 頁： 175 - 82 2012年3月

Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients

Arase, Y; Kobayashi, M; Suzuki, F; Suzuki, Y; Kawamura, Y; Akuta, N; Imai, N; Kobayashi, M; Sezaki, H; Matsumoto, N; Saito, S; Hosaka, T; Ikeda, K; Kumada, H; Ohmoto, Y; Amakawa, K; Hsieh, SD; Ogawa, K; Tanabe, M; Tsuji, H; Kobayashi, T

HEPATOLOGY RESEARCH 42 巻 ( 3 ) 頁： 264 - 272 2012年3月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Hepatology Research

Aim: Malignancies that include hepatocellular carcinoma often occurred in patients with chronic liver disease. The aim of this retrospective match control study was to assess the cumulative development incidence and predictive factors for total malignancies in elderly Japanese patients with non-alcoholic hepatic diseases (NAFLD) or hepatitis C virus (HCV). Methods: A total of 1600 NAFLD patients with age of ≥60years were enrolled, and 1600 HCV patients with age of ≥60years were selected as control by matching 1:1 with NAFLD group for age, sex, and follow-up period. The primary goal is the first development of malignancies. Evaluation was performed by the use of the Wilcoxon rank sum test, the Kaplan-Meier method, and Cox proportional hazard model. The mean observation period is 8.2years in both NAFLD and HCV group, respectively. Results: The number of patients with the development of malignancies was 167 in the NAFLD group and 395 in the HCV group. The 10th development rate of malignancies was 13.9% in the NAFLD group and 28.2% in the HCV group (risk ratio 2.27; P<0.001). The incident rates of hepatocellular carcinoma in all the malignancies were 6.0% (10/167) in the NAFLD group and 67.6% (267/395) in the HCV group (P<0.001). The malignancies in the NAFLD group were observed in the following order: gastric cancer 34 cases (20.4%)>colon cancer 31 cases (18.6%)>prostate cancer 21 cases (12.6%). Conclusions: The incident rates of hepatocellular carcinoma in all the malignancies were approximately 6% in the NAFLD group and two-thirds in the HCV group. © 2011 The Japan Society of Hepatology.

DOI： 10.1111/j.1872-034X.2011.00915.x

Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.

Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H

The American journal of gastroenterology 107 巻 ( 2 ) 頁： 253 - 61 2012年2月

慢性腎不全合併肝細胞癌に対するミリプラチン肝動脈化学療法の安全性と有効性

今井則博, 池田健次, 瀬古裕也, 松本直樹, 川村祐介, 保坂哲也, 小林正宏, 斎藤聡, 瀬崎ひとみ, 芥田憲夫, 鈴木文孝, 鈴木義之, 荒瀬康司, 熊田博光

日本消化器病學會雜誌 = The Japanese journal of gastro-enterology 108 巻 ( 11 ) 頁： 1872-1878 - 1878 2011年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：一般財団法人日本消化器病学会

ミリプラチン投与症例より投与前の推定クレアチニン・クリアランス（以下推定Ccr）が60ml/min未満67例，60ml/min以上95例を対象とし推定Ccrの変化，副作用，有効性について検討した．慢性腎不全群における治療後2カ月の間の推定Ccr値（中央値）は治療前後の補液による上昇の他に明らかな低下を認めなかった（治療前；46ml/min，1週間後；52ml/min，1カ月後；48ml/min，2カ月後；45ml/min，P<0.0001）．ミリプラチン投与による重篤な副作用は認められなかった．ミリプラチンは慢性腎不全を合併した肝細胞癌に対する白金製剤として，その安全性が示唆された．

DOI： 10.11405/nisshoshi.108.1872

researchmap

Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure

Imai N.

Journal of Japanese Society of Gastroenterology 108 巻 ( 11 ) 頁： 1872-1878 2011年11月

Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy

ARASE Yasuji, SUZUKI Fumitaka, KAWAMURA Yusuke, SUZUKI Yoshiyuki, KOBAYASHI Masahiro, MATSUMOTO Naoki, AKUTA Norio, SEZAKI Hitomi, HOSAKA Tetsuya, OGAWA Kyoko, IMAI Norihiro, SEKO Yuya, SAITO Satoshi, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

Hepatology research : the official journal of the Japan Society of Hepatology 41 巻 ( 10 ) 頁： 946 - 954 2011年10月

　前のページ - 次のページ　

<今井 則博>

論文 - 今井 則博

<今井　則博>

論文 - 今井　則博